Clearmind Medicine Inc.
NASDAQ Capital MarketTotal Valuation
Clearmind Medicine Inc. carries a market capitalization of 1.67M, placing it among publicly traded companies globally. Its enterprise value stands at -12.48M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.67M |
| Enterprise Value | -12.48M |
Share Statistics
Clearmind Medicine Inc. currently has 1.02M shares outstanding.
| Shares Outstanding | 1.02M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.12 |
| P/TBV Ratio | 0.09 |
| P/FCF Ratio | -0.16 |
| P/OCF Ratio | -0.16 |
Financial Position
Clearmind Medicine Inc. maintains a current ratio of 4.79, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.74, indicating moderate leverage, while an interest coverage ratio of -712.11 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.79 |
| Quick Ratio | 4.73 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | -712.11 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -80.22 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 17,723.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Clearmind Medicine Inc.'s stock has declined approximately -99.63717% over the past 52 weeks. The 50-day moving average sits at 2.97, while the 200-day moving average is 68.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.63717% |
| 50-Day Moving Average | 2.97 |
| 200-Day Moving Average | 68.38 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -8.04M, while operating income came in at -8.10M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -8.10M |
| Pretax Income | -7.89M |
| Net Income | -7.90M |
| EBITDA | -8.04M |
| EBIT | -8.10M |
| Earnings Per Share (EPS) | -54.95 |
Balance Sheet
Clearmind Medicine Inc. holds 13.59M in cash and equivalents against 85,588.00 in total debt, resulting in a net debt position of -11.42M. Total book value stands at 8.88M, with working capital of 11.33M providing operational flexibility.
| Cash & Cash Equivalents | 13.59M |
| Total Debt | 85,588.00 |
| Net Debt | -11.42M |
| Equity (Book Value) | 8.88M |
| Book Value Per Share | 61.74 |
| Working Capital | 11.33M |
Cash Flow
Clearmind Medicine Inc. produced -6.22M in operating cash flow over the past twelve months.
| Operating Cash Flow | -6.22M |
| Capital Expenditures | N/A |
| Free Cash Flow | -6.22M |
| FCF Per Share | -43.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -1,388.77 |
| FCF Yield | -607.69 |
Stock Splits
Clearmind Medicine Inc.'s most recent stock split took place on May 21, 2026 with a 10:1 split ratio.
| Last Split Date | 5/21/2026 |
| Split Ratio | 10:1 |
Scores
Clearmind Medicine Inc. posts an Altman Z-Score of -3.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -3.98 |